Email updates

Keep up to date with the latest news and content from Trials and BioMed Central.

Open Access Study protocol

Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSeal™: study protocol of a randomized controlled trial

Ruzica Rosalia Luketina1*, Michael Knauer1, Gernot Köhler1, Oliver Owen Koch1, Klaus Strasser2, Margot Egger3 and Klaus Emmanuel1

Author Affiliations

1 Department of General and Visceral Surgery, Krankenhaus der Barmherzigen Schwestern Linz, Seilerstätte 4, Linz 4020, Austria

2 Department of Anaesthesiology, Krankenhaus der Barmherzigen Schwestern Linz, Seilerstätte 4, Linz 4020, Austria

3 Department of Laboratory Medicine, Krankenhaus der Barmherzigen Schwestern Linz, Seilerstätte 4, Linz 4020, Austria

For all author emails, please log on.

Trials 2014, 15:239  doi:10.1186/1745-6215-15-239

Published: 20 June 2014

Abstract

Background

AirSeal™ is a novel class of valve-free insufflation system that enables a stable pneumoperitoneum with continuous smoke evacuation and carbon dioxide (CO2) recirculation during laparoscopic surgery. Comparison data to standard CO2 pressure pneumoperitoneum insufflators is scarce. The aim of this study is to evaluate the potential advantages of AirSeal™ compared to a standard CO2 insufflator.

Methods/Design

This is a single center randomized controlled trial comparing elective laparoscopic cholecystectomy, colorectal surgery and hernia repair with AirSeal™ (group A) versus a standard CO2 pressure insufflator (group S). Patients are randomized using a web-based central randomization and registration system. Primary outcome measures will be operative time and level of postoperative shoulder pain by using the visual analog score (VAS). Secondary outcomes include the evaluation of immunological values through blood tests, anesthesiological parameters, surgical side effects and length of hospital stay. Taking into account an expected dropout rate of 5%, the total number of patients is 182 (n = 91 per group). All tests will be two-sided with a confidence level of 95% (P <0.05).

Discussion

The duration of an operation is an important factor in reducing the patient’s exposure to CO2 pneumoperitoneum and its adverse consequences. This trial will help to evaluate if the announced advantages of AirSeal™, such as clear sight of the operative site and an exceptionally stable working environment, will facilitate the course of selected procedures and influence operation time and patients clinical outcome.

Trial registration

ClinicalTrials.gov NCT01740011, registered 23 November 2012.

Keywords:
Pneumoperitoneum; AirSeal™; Laparoscopy; CO2 Insufflator; Shoulder pain